Image 1
Chemical structure of clonidine showing a dichlorobenzene ring connected to an imidazoline ring, illustrating its molecular framework.*
Clonidine Transdermal System Patch
Product Images NDC 0591-3509
14 FDA label images from Actavis Pharma, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Clonidine Transdermal System (NDC 0591-3509). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image 10
Clonidine transdermal system 0.1 mg/day patch carton label from Actavis Pharma, Inc. The label indicates the package contains 4 systems and 4 adhesive covers. It includes warnings to remove the patch before MRI procedures and states it is for transdermal use only. "NO COAT" is printed multiple times on the label.*
Image 11
Clonidine Transdermal System USP patch label by Actavis Pharma, Inc. for 0.2 mg/day strength. The label states it is Rx only and contains 4 systems and 4 adhesive covers. It includes instructions to remove the patch before MRI procedure and storage conditions of 20° to 25°C. The package contains 4 transdermal systems with inactive components listed.*
Image 12
Box label for Clonidine transdermal system, USP 0.2 mg/day patch by Actavis Pharma, Inc. The label states active ingredient Clonidine with a dosage strength delivering 0.2 mg per day, supplied as a transdermal system patch. The package contains 4 systems and 4 adhesive covers, with instructions and MRI warnings noted. NDC 0591-3509 is visible.*
Image 13
Clonidine Transdermal System, USP 0.3 mg/day patch carton by Actavis Pharma, Inc. The label highlights in vivo delivery of 0.3 mg clonidine per day for one week. The package contains 4 systems and 4 adhesive covers. It includes warnings about patch removal before MRI and storage instructions at 20° to 25°C (68° to 77°F).*
Image 14
Clonidine transdermal system 0.3 mg/day patch packaging label. The label shows the product name, strength, and dosage form. It also states the quantity of 4 systems and 4 adhesive covers, with usage instructions and caution for MRI procedures. The labeler is Actavis Pharma, Inc., and the label includes multiple 'NO COAT' markings and barcode details.*
Image 2
An instructional diagram showing the layered components of the Clonidine transdermal system patch. The layers include the secondary protective liner, backing, drug reservoir, control membrane, adhesive, and release liner, with notes to remove the liners prior to use.*
Image 3
An instructional diagram showing the placement of the Clonidine transdermal system patch on the upper arm. It indicates the patch location and the optional application of an adhesive cover over the patch if necessary.*
Image 4
Clonidine transdermal system 0.1 mg/day patch label by Actavis Pharma, Inc. The label indicates the patch delivers 0.1 mg clonidine per day for one week. It includes a warning to remove the patch before an MRI to avoid burns. The image also shows an adhesive cover label for use if the patch becomes loose, stating it contains no active medication and should be applied over the patch as needed.*
Image 5
Illustration showing hands peeling open the packaging of a Clonidine transdermal system patch. The patch label includes the proprietary name, and it is depicted being removed from its protective pouch as part of usage instructions.*
Image 6
An instructional illustration showing a pair of hands applying or handling a small square patch, likely demonstrating the placement or removal technique for the Clonidine transdermal system patch.*
Image 7
An instructional illustration showing a person applying a patch to their upper arm. The figure highlights correct placement and application technique for the clonidine transdermal system patch.*
Image 8
Illustration showing the adhesive cover of the Clonidine transdermal system patch. The cover is labeled with a warning stating it does not contain active medication and should be applied over the patch if necessary. The image highlights instructions for proper patch use by Actavis Pharma, Inc.*
Image 9
Clonidine transdermal system, USP 0.1 mg/day patch by Actavis Pharma, Inc. This packaging contains 4 transdermal systems and 4 adhesive covers. The label includes dosing strength, manufacturer and distributor information, and usage instructions noting removal before MRI. The product is for transdermal use only and carries an Rx only designation.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
